These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 17295644)
1. Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. Ichihara S; Fujimoto T; Hashimoto K; Moritani S; Hasegawa M; Yokoi T Pathol Int; 2007 Mar; 57(3):126-32. PubMed ID: 17295644 [TBL] [Abstract][Full Text] [Related]
2. Myoepithelial cells in solid variant of intraductal papillary carcinoma of the breast: a potential diagnostic pitfall and a proposal of an immunohistochemical panel in the differential diagnosis with intraductal papilloma with usual ductal hyperplasia. Moritani S; Ichihara S; Kushima R; Okabe H; Bamba M; Kobayashi TK; Hattori T Virchows Arch; 2007 May; 450(5):539-47. PubMed ID: 17377808 [TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic and immunohistochemical study of 187 cases of intraductal papillary neoplasm of breast]. Zhang H; Xiong Y; Zhang S; Zhang Y; Wang YH; Li T Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):726-31. PubMed ID: 22336153 [TBL] [Abstract][Full Text] [Related]
4. The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. Tse GM; Tan PH; Lui PC; Gilks CB; Poon CS; Ma TK; Law BK; Lam WW J Clin Pathol; 2007 Mar; 60(3):315-20. PubMed ID: 16698948 [TBL] [Abstract][Full Text] [Related]
5. Solid papillary ductal carcinoma in situ versus usual ductal hyperplasia in the breast: a potentially difficult distinction resolved by cytokeratin 5/6. Rabban JT; Koerner FC; Lerwill MF Hum Pathol; 2006 Jul; 37(7):787-93. PubMed ID: 16784976 [TBL] [Abstract][Full Text] [Related]
6. The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. Tse GM; Tan PH; Moriya T J Clin Pathol; 2009 May; 62(5):407-13. PubMed ID: 19126567 [TBL] [Abstract][Full Text] [Related]
7. [Papillary lesions of the breast]. Ni YB; Tse GM Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):721-6. PubMed ID: 24447546 [No Abstract] [Full Text] [Related]
8. Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? Tan PH; Aw MY; Yip G; Bay BH; Sii LH; Murugaya S; Tse GM Am J Surg Pathol; 2005 May; 29(5):625-32. PubMed ID: 15832086 [TBL] [Abstract][Full Text] [Related]
9. Cytokeratin 5 and estrogen receptor immunohistochemistry as a useful adjunct in identifying atypical papillary lesions on breast needle core biopsy. Grin A; O'Malley FP; Mulligan AM Am J Surg Pathol; 2009 Nov; 33(11):1615-23. PubMed ID: 19675450 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of 14-3-3 sigma and related proteins in hyperplastic and neoplastic breast lesions, with particular reference to early carcinogenesis. Simooka H; Oyama T; Sano T; Horiguchi J; Nakajima T Pathol Int; 2004 Aug; 54(8):595-602. PubMed ID: 15260850 [TBL] [Abstract][Full Text] [Related]
11. Papillary neoplasia of the breast: immunohistochemically defined myoepithelial cells in the diagnosis of benign and malignant papillary breast neoplasms. Raju UB; Lee MW; Zarbo RJ; Crissman JD Mod Pathol; 1989 Nov; 2(6):569-76. PubMed ID: 2479944 [TBL] [Abstract][Full Text] [Related]
12. Breast pathology practice: most common problems in a consultation service. Putti TC; Pinder SE; Elston CW; Lee AH; Ellis IO Histopathology; 2005 Nov; 47(5):445-57. PubMed ID: 16241992 [TBL] [Abstract][Full Text] [Related]
13. Diminished number or complete loss of myoepithelial cells associated with metaplastic and neoplastic apocrine lesions of the breast. Tramm T; Kim JY; Tavassoli FA Am J Surg Pathol; 2011 Feb; 35(2):202-11. PubMed ID: 21263240 [TBL] [Abstract][Full Text] [Related]
14. Nestin is expressed in the basal/myoepithelial layer of the mammary gland and is a selective marker of basal epithelial breast tumors. Li H; Cherukuri P; Li N; Cowling V; Spinella M; Cole M; Godwin AK; Wells W; DiRenzo J Cancer Res; 2007 Jan; 67(2):501-10. PubMed ID: 17234757 [TBL] [Abstract][Full Text] [Related]
15. A useful immunohistochemical approach to evaluate intraductal proliferative lesions of the breast and to predict their prognosis. Omi Y; Yamamoto T; Okamoto T; Obara T; Kobayashi M Histol Histopathol; 2011 Jan; 26(1):79-86. PubMed ID: 21117029 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical staining of papillary breast lesions. Troxell ML; Masek M; Sibley RK Appl Immunohistochem Mol Morphol; 2007 Jun; 15(2):145-53. PubMed ID: 17525625 [TBL] [Abstract][Full Text] [Related]
17. Significance of papillary lesions at percutaneous breast biopsy. Valdes EK; Tartter PI; Genelus-Dominique E; Guilbaud DA; Rosenbaum-Smith S; Estabrook A Ann Surg Oncol; 2006 Apr; 13(4):480-2. PubMed ID: 16474908 [TBL] [Abstract][Full Text] [Related]
18. Ductal epithelial proliferations of the breast: a biological continuum? Comparative genomic hybridization and high-molecular-weight cytokeratin expression patterns. Boecker W; Buerger H; Schmitz K; Ellis IA; van Diest PJ; Sinn HP; Geradts J; Diallo R; Poremba C; Herbst H J Pathol; 2001 Nov; 195(4):415-21. PubMed ID: 11745672 [TBL] [Abstract][Full Text] [Related]
19. Papillomas and atypical papillomas in breast core needle biopsy specimens: risk of carcinoma in subsequent excision. Renshaw AA; Derhagopian RP; Tizol-Blanco DM; Gould EW Am J Clin Pathol; 2004 Aug; 122(2):217-21. PubMed ID: 15323138 [TBL] [Abstract][Full Text] [Related]
20. Loss of myoepithelium is variable in solid papillary carcinoma of the breast. Nicolas MM; Wu Y; Middleton LP; Gilcrease MZ Histopathology; 2007 Nov; 51(5):657-65. PubMed ID: 17927587 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]